Pulmonary Alveolar Proteinosis in Greece–Türkiye–Cyprus: Answers in a Real‐Life Comparison
Respirology · 2026
DOI: 10.1002/resp.70288 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Respirology, 2026. Verfasst von Spyros A Papiris und 42 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Pulmonary Alveolar Proteinosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background and Objective Pulmonary alveolar proteinosis (PAP) is a rare disease of inappropriate alveolar surfactant accumulation. The study objective was to compare Greece–Türkiye–Cyprus cohorts, followed‐up for 20 years.
Methods
Data were retrieved retrospectively by chart review.
Results
One hundred and thirty patients, Greece 39, Türkiye 87, Cyprus 4, were included; 115 (89%) autoimmune (a)PAP, 13 (10%) secondary, 1 (1%) hereditary. Abnormal anti‐GM‐CSF antibody titre was available in 86/115 patients, further analyzed for aPAP. Forty (46%) were male, with median (IQR) age at diagnosis of 40 (31–50) years. At median (IQR) duration of clinical follow‐up of 39 (18–78) months, three patients died. Non‐survivors had higher rates of cardiovascular disease [67% vs. 5%, p < 0.001], LTOT (67% vs. 13%, p = 0.001), pulmonary fibrosis [67% vs. 5%] and worse functional status at follow‐up [FVC% pred 49 (29) vs. 87 (74–97); p = 0.026, DLCO% pred 21 (46) vs. 72 (58–82); p = 0.016]. aPAP patients were stratified by therapy group (no WLL‐no i‐GM‐CSF, WLL alone, i‐GMCSF alone and both WLL and iGM‐CSF). WLL was more frequently performed in Türkiye and i‐GMCSF alone in Greece ( p = 0.006). All therapies were effective. No difference was detected on outcome when sole iGM‐CSF was compared to WLL alone or in combination with iGM‐CSF [deceased/alive 0%/100% vs. 7%/93%, p = 0.491]. Sole iGM‐CSF significantly ameliorated clinical and functional parameters of disease severity [DLCO% ( p = 0.013), SatO 2 ( p = 0.002), 6MWT ( p = 0.026)]. Across all therapy groups, pulmonary fibrosis eliminated beneficial response to treatment.
Conclusion
This first real‐life comparison of aPAP cohorts originating from three countries showed the non‐inferiority of sole iGM‐CSF treatment. Fibrosis negatively affects response to treatment and survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Yedikule Chest Diseases and Thoracic Surgery, Education and Research Hospital, University of Health Sciences, İstanbul, Türkiye.
- 2nd Pulmonary Medicine Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Pulmonary Medicine, Ege University Medical School, Ege University Hospital, Izmir, Türkiye.
- 1st Respiratory Medicine Department, "Sotiria" Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Pulmonary Medicine Department, Larnaca General Hospital, Larnaca, Cyprus.
ORCID-Profile: Nesrin Mogulkoc, Ezgi Demirdöğen, Emmanouil Verykakis, Anastasia Levounets, Kalliopi Vandorou, Spyridon Prountzos, Brenna Carey, Matthias Griese, Effrosyni D Manali
Förderung
- Deutsche Forschungsgemeinschaft
- NIH HHS
- National Institutes of Health
Zitieren
APA
Papiris, S. A., Chousein, E. G. U., Kallieri, M., Mogulkoc, N., Papaioannou, A. I., Frangopoulos, F., Adamide, T., Kolilekas, L., Gökçe, B., Ocal, N., Papakosta, D., Özyürek, B. A., Tzilas, V., Yalnız, E., Kontonasiou, G., Demirdöğen, E., Verykakis, E., Ursavaş, A., Antonogiannaki, E. M., …, & Manali, E. D. (2026). Pulmonary Alveolar Proteinosis in Greece–Türkiye–Cyprus: Answers in a Real‐Life Comparison. Respirology. https://doi.org/10.1002/resp.70288
Vancouver
Papiris SA, Chousein EGU, Kallieri M, Mogulkoc N, Papaioannou AI, Frangopoulos F, et al. Pulmonary Alveolar Proteinosis in Greece–Türkiye–Cyprus: Answers in a Real‐Life Comparison. Respirology. 2026. doi:10.1002/resp.70288
BibTeX
@article{Papiris2026,
author = {Papiris, Spyros A and Chousein, Efsun Gonca Uğur and Kallieri, Maria and Mogulkoc, Nesrin and Papaioannou, Andriana I and Frangopoulos, Frangiskos and Adamide, Tonia and Kolilekas, Lykourgos and Gökçe, Burak and Ocal, Nesrin and Papakosta, Despina and Özyürek, Berna Akıncı and Tzilas, Vasilios and Yalnız, Enver and Kontonasiou, Georgia and Demirdöğen, Ezgi and Verykakis, Emmanouil and Ursavaş, Ahmet and Antonogiannaki, Elvira-Markela and Deniz, Pelin Pınar and Apollonatou, Vasiliki and Hanta, Ismail and Chatzis, Dimitrios and Levounets, Anastasia and Olympiou, Nicoletta and Vandorou, Kalliopi and Dimeas, Ilias and Daniil, Zoe and Roussakis, Nikolaos and Schams, Andrea and Monnier, Delphine and Rampiadou, Christina and Steiropoulos, Paschalis and Markopoulou, Katerina and Tzanakis, Nikolaos and Gourgoulianis, Konstantinos and Prountzos, Spyridon and Bouros, Demosthenes and Carey, Brenna and Trapnell, Bruce and Griese, Matthias and Çetinkaya, Erdoğan and Manali, Effrosyni D},
title = {Pulmonary Alveolar Proteinosis in Greece–Türkiye–Cyprus: Answers in a Real‐Life Comparison},
journal = {Respirology},
year = {2026},
doi = {10.1002/resp.70288}
}
EUVIMED